Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 6/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 7/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30174228 | 0.89 | MKNK1 (0.39) | ACACB | |
| SCHEMBL30061627 | 0.86 | MYC (0.47) | MYCCTSBKLKB1ELANEMMP9 | |
| SCHEMBL25528995 | 0.86 | MYC (0.47) | MYCCTSBKLKB1ELANEMMP9 | |
| SCHEMBL25528993 | 0.81 | MYC (0.50) | MYCCTSBKLKB1ELANEMMP9 | |
| SCHEMBL30174241 | 0.81 | MYC (0.50) | MYCCTSBKLKB1ELANEMMP9 | |
| SCHEMBL25217521 | 0.80 | MYC (0.52) | MYCCTSBKLKB1ELANEMMP9 | |
| SCHEMBL25235127 | 0.79 | MYC (0.39) | MYCCTSBKLKB1ELANEMMP9 | |
| SCHEMBL25227865 | 0.79 | MYC (0.48) | MYCCTSBKLKB1ELANEMMP9 | |
| SCHEMBL30174308 | 0.76 | NNMT (0.45) | MYCCTSBKLKB1ELANEMMP9 | |
| SCHEMBL25528987 | 0.75 | MYC (0.47) | MYCCTSBKLKB1ELANEMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | EXELIXIS INC (US) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151003-A1 | COMPOUNDS AND METHODS OF USE | PRKACB, PRKACA, PRKX | MYC 764/4885CTSB 2140/4885KLKB1 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.